Implementing ADCC assays in QC: When donor variability isn’t an option
ABOUT THIS WEBINAR:
Inherent donor variability of immune effector cells presents a significant challenge for developing a robust and reproducible ADCC assays for QC lot release. DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
The webinar focused on 2 qualification studies that were performed using these effectors to demonstrate accuracy and precision in different assay formats.
KEYNOTE SPEAKERS:
Laura’s background in immunology has provided extensive experience for her current role in developing and qualifying Bioassays and ELISAs for use in the characterisation of monoclonal antibodies.
Lisa joined BioOutsource as an assay development scientist, responsible for development and qualification of cell-based and binding assays for biosimilar comparability and characterisation studies.
Alpana manages DiscoverX’s biologics & immuno-oncology products, and has extensive experience in marketing life sciences products & biosimilars. She has a PhD in Biochemistry from University of Oxford.
The rest of this content is restricted - login or subscribe free to access
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Antibodies, Assays, Cell-based assays, cytotoxicity, Cytotoxicity assays, Immunoassays, Protein, Screening
Related organisations
Eurofins Discovery, Sartorius Stedim BioOutsource Limited